Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: Two case reports

RATIONAL: The efficacy of nintedanib, a multitarget receptor tyrosine kinase inhibitor, has been demonstrated in recent randomized controlled trials involving patients with idiopathic pulmonary fibrosis (IPF). However, accelerated disease progression after nintedanib discontinuation has never been r...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamori, Satoshi, Asakura, Takanori, Masuzawa, Keita, Yasuda, Hiroyuki, Kamata, Hirofumi, Ishii, Makoto, Betsuyaku, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728940/
https://www.ncbi.nlm.nih.gov/pubmed/29245325
http://dx.doi.org/10.1097/MD.0000000000009081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728940/
https://www.ncbi.nlm.nih.gov/pubmed/29245325
http://dx.doi.org/10.1097/MD.0000000000009081

Ejemplares similares